

Newsletter

2014 / Nr. 2

March 2014

Dear colleagues and EUGenMed friends!

We are reaching the first milestones!

Milestone 1:

We have built a homepage, we have assembled a first group of stakeholders and we have started the discussions!

Milestone 2:

Our kick-off conference will be taking place in Brussels on April 7th from 9.30 to 17.00. 80 invited experts agreed to participate, sent statements, registration forms and CV's. EUGenMed aims to assess the status quo of Gender Medicine (GM) in Europe and to develop a roadmap for the implementation of sex and gender (S&G) in biomedical sciences and health research. The four sessions at our kick off conference will aid in preparing four focused workshops later in 2014. The kick-off conference, defines the most relevant topics, experts and stakeholders to be invited to the subsequent workshops for in depth discussions. We aim to contact as many stakeholders and opinion leaders in Gender Medicine as possible. For those who are unable to attend we will provide a detailed report of the conference in due course on the EUGenMed homepage.

If you are unable to attend the first conference in Brussels, please visit our website after the meeting to find all the reports about the conference and check out the opportunities to contribute to the upcoming thematic workshops.

We are looking forward to your contribution to this groundbreaking project!



Prof. Vera Regitz-Zagrosek

<http://www.eugenmed.eu/>

EUGenMed Coordinator; Director, Institute for Gender Medicine, Charité

Kick-off conference, Brussels, 7th of April

In **session 1**, the conference will develop an outline for 4 workshops to be held later in 2014: **Session 1.1** will identify the most salient gender topics in the area of **clinical medicine and pharmacology** and will outline which of them are already covered by EU or national research programs and where we still have unmet needs. It will also set priorities for research

Session 1.2 will discuss **Sex and gender aspects of public health and prevention**, including occupational health, screening programs for women and men, sex and gender specific lifestyle risk factors.

Session 1.3 will cover **sex differences in basic research** (epi/genetics, stem cells, aging and regeneration, cell and animal models), preclinical drug development, and appropriate statistics for analysis.

Session 1.4 will concentrate on **current medicines regulations**, clinical trials, legislation, GCP guidelines and research policies and the integration of gender in medical training.

Session 2 will identify **target audiences and potential contributors for the communication of gender issues**. At issue in this session is to instigate stakeholders' involvement, participation and consensus in the implementation of S&G in biomedical sciences, practices and health research in Europe.

Session 3 will discuss **effective communication strategies**. Participants will identify appropriate materials and tools to communicate the importance of considering S&G issues to the different target audiences, such as policy briefs on different diseases, journal articles, tools for medical training and discussion on the use of social media for targeting the different stakeholders.

In a final **plenary session**, we will discuss the results of the sessions and decide on the workshops for the next phase.

More team members

In our last newsletter (see homepage) we introduced the main project partners. We are now introducing the scientists working at partner sites that are supporting the development of the project:

Lucie Dalibert, PhD, MA, is a postdoctoral researcher in the EUGenMed project. Trained in political sciences, gender studies and philosophy of technology, she is especially involved in the project's public health and prevention dimension. Lucie is particularly interested in questions of embodiment and practices of exclusion/inclusion in relation to science and technology.

Sabine Oertelt-Prigione, MD, MScPH, is trained in Internal Medicine and analysed the role of sex in autoimmunity during her first postdoc. She is now focussing on the inclusion of gender aspects into preventive measures and implementation strategies. The range of her interests spans from cardiovascular prevention to the prevention of sexual harassment at the workplace.

Ute Seeland, MD, is a specialist in internal medicine with main skills in cardiovascular research and gender specific knowledge. She developed an eLearning course "eGender Medicine" to harmonise and to spread gender medicine knowledge in Europe. Other research topics are "novel" risk factors in cardiovascular diseases, e.g. pregnancy complications, and vascular stiffness.

Kristin Semancik, BA, MA, has extensive experience in government, academia, industry, research and the non-profit sector in health and in politics. She is completing her Ph.D. at Trinity College Dublin on the effects of the EU on healthcare systems. As EIWH Research and Policy Officer, she has worked on various EU projects, including ENGENDER.

Planned meetings

7. April 2014

Kick-off conference

Workshops:

WS 1, Sex and Gender differences in clinical medicine and pharmacology.

WS 2, Sex and Gender aspects in public health and prevention.

WS 3, Sex and Gender aspects in basic biomedical research.

WS 4, Sex and Gender in medicines regulation and medical education

Roadmap conference

Brussels

Brussels



This project the European Gender Medicine Network (EUGenMed) has received funding from the European Union's Seventh Framework Programme for research, technological development and demonstration under grant agreement No 602050.